Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Xencor Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners across 4 distinct art units, so each pending matter has a separate examiner assignment even though some art-unit overlap exists.
DUFFY, BRADLEY is the busiest examiner, with 1 pending matter. No examiner accounts for more than that listed figure, making individual file review and deadline control the practical focus for the current portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.7% | +47.4% |
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634868 | ANTI-CD28 X ANTI-ENPP3 ANTIBODIES | NATARAJAN, MEERA | — |
| 18503935 | IL18-FC FUSION PROTEINS | DONOGHUE, BRITTNEY ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033165 | ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | 97d overdue |
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | AEDER, SEAN E | 16d |
| 19668578 | METHODS FOR TREATING IgG4-RELATED DISEASES | DUFFY, BRADLEY | — |
| 18634868 | ANTI-CD28 X ANTI-ENPP3 ANTIBODIES | NATARAJAN, MEERA | — |
| 18503935 | IL18-FC FUSION PROTEINS | DONOGHUE, BRITTNEY ERIN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 1642 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19668578 | METHODS FOR TREATING IgG4-RELATED DISEASES | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | — | Pending | May 05, 2026 |
| 18634868 | ANTI-CD28 X ANTI-ENPP3 ANTIBODIES | NATARAJAN, MEERA | 1643 | §103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | AEDER, SEAN E | 1642 | §112Other | Final Rejection | 16d | Pending | Feb 26, 2024 |
| 18503935 | IL18-FC FUSION PROTEINS | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112 | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18033165 | ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | 1643 | §103DP | Final Rejection | 97d overdue | Pending | Apr 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXencor Inc. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Bradley Duffy has the most, with 1 of Xencor Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
